Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy

Marina Noris; Roberta Donadelli; Giuseppe Remuzzi

doi:10.1007/s00467-018-3989-0

Back

Related publications

Article2015

Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015

Marina Noris, Giuseppe Remuzzi

Article2021

CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis

Rossella Piras, Matteo Breno, Elisabetta Valoti, Marta Alberti, Paraskevas Iatropoulos, Caterina Mele, Elena Bresin, Roberta Donadelli, Paola Cuccarolo, Richard J. Smith, Ariela Benigni, Giuseppe Remuzzi, Marina Noris

Article2013

Prevalence of C3 mutations in primary membranoproliferative glomerulonephritis

Elisabetta Valoti, Elena Bresin, Rossella Piras, Marta Alberti, Annalisa Sorosina, Roberta Donadelli, Giuseppe Remuzzi, Marina Noris

Article2020

LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy

Edwin Wong, Manuel Praga, Carla Nester, Erica Daina, Giuseppe Remuzzi, Prasanna Kumar Nidamarthy, Peter End, Julie M. Milojevic, Andrea Biondani, Angelo J. Trapani, Nicholas J.A. Webb, Dr Guido Junge

Article2009

aHUS-associated genetic complement abnormalities cause C3 deposition on endothelial cells: Protective effects of specific inhibitors of the alternative pathway of complement

Sara Gastoldi, Miriam Galbusera, Woodruff Emlen, V. Michael Holers, Federica Banterla, Roberta Donadelli, Giuseppe Remuzzi, Marina Noris